InkVivo accelerates its iron deficiency anemia program

The ETH Zurich spin-off is advancing three programs based on its proprietary drug delivery platforms. Its lead candidate for the treatment of iron deficiency anemia is approaching human validation, while a second program targeting neurodegenerative diseases is progressing through preclinical development.

Read the full article: https://www.startupticker.ch/en/news/inkvivo-advances-iron-deficiency-anemia-program-toward-human-validation